Phaseline

Companies › Taiho Oncology

Taiho Oncology: clinical trials, targets and expected readouts

7 active drug programs in 19 registered trials: 9 Phase 2, 7 Phase 1, 3 Phase 3; Oncology, Hematology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Cln-081 (TAS6417)
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 3Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation; Lung Cancer; Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) MutationsMay 2027
Futibatinib (TAS-120)
Fibroblast growth factor receptor inhibitor
FGFR3, FGFR1, FGFR4, FGFR2Phase 2Advanced Cholangiocarcinoma; Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer; Advanced/Metastatic Cancer; Biliary Tract Neoplasms …Dec 2026
Azacitidine (ASTX030)
DNA (cytosine-5)-methyltransferase 3A inhibitor; DNA (cytosine-5)-methyltransferase 1 inhibitor
DNMT3A, DNMT1Phase 2Myelodysplastic SyndromesNov 2027
Cedazuridine
Cytidine deaminase inhibitor
CDAPhase 2Myelodysplastic Syndromes; Solid TumorNov 2027
Decitabine (ASTX727)
DNA (cytosine-5)-methyltransferase 3A inhibitor; DNA (cytosine-5)-methyltransferase 1 inhibitor
DNMT3A, DNMT1Phase 1Acute Myeloid LeukemiaDec 2026
ASTX660
IAP inhibitor
IAPPhase 1Solid Tumors; Advanced CancerDec 2027
ARC-02–Phase 1B-cell Non Hodgkin LymphomaJan 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03767075Futibatinib (TAS-120)Phase 2Advanced Solid TumorOncologyNov 2026
NCT05727176Futibatinib (TAS-120)Phase 2Advanced CholangiocarcinomaOncologyDec 2026
NCT04953897Decitabine (ASTX727)Phase 1Acute Myeloid LeukemiaOncologyDec 2026
NCT04953910Decitabine (ASTX727)Phase 1Acute Myeloid LeukemiaOncologyDec 2026
NCT05082259ASTX660Phase 1Advanced CancerOncologyDec 2026
NCT05945823Futibatinib (TAS-120)Phase 2Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal CancerOncologyJan 2027
NCT03875287CedazuridinePhase 1Solid TumorOncologyMar 2027
NCT06506955Futibatinib (TAS-120)Phase 2Advanced/Metastatic CancerOncologyApr 2027
NCT05973773Cln-081 (TAS6417)Phase 3Advanced or Metastatic NSCLS With Exon 20 Insertion MutationOncologyMay 2027
NCT05615818Futibatinib (TAS-120)Phase 3Biliary Tract NeoplasmsOncologyJun 2027
NCT06263153Futibatinib (TAS-120)Phase 2Bladder Urothelial CarcinomaOncologyJul 2027
NCT04256317Azacitidine (ASTX030)Phase 2Myelodysplastic SyndromesHematologyNov 2027
NCT04256317CedazuridinePhase 2Myelodysplastic SyndromesHematologyNov 2027
NCT02503423ASTX660Phase 1Solid TumorsOncologyDec 2027
NCT06722183Futibatinib (TAS-120)Phase 2Colorectal CancerOncologyMar 2028
NCT05967689Cln-081 (TAS6417)Phase 2Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) MutationsOncologyAug 2028
NCT04657081Decitabine (ASTX727)Phase 1Acute Myeloid LeukemiaOncologyDec 2028
NCT07691606ARC-02Phase 1B-cell Non Hodgkin LymphomaOncologyJan 2029
NCT07128199Cln-081 (TAS6417)Phase 3Lung CancerOncologyOct 2029

Targets

DNMT3A (2) DNMT1 (2) FGFR3 (1) FGFR1 (1) FGFR4 (1) FGFR2 (1) IAP (1) CDA (1) EGFR (1)

Companies with the same targets

Tyra Biosciences Johnson & Johnson (Janssen) AstraZeneca Exelixis QED Therapeutics, a BridgeBio company TransThera Sciences (Nanjing) Hutchmed Eisai EpiDestiny AbbVie

Companies built like this

Abbisko Therapeutics Jiangsu Alphamab Biopharmaceuticals Dizal Pharmaceuticals Nanjing Sanhome Pharmaceutical Jiangsu Aosaikang Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.